At its second attempt, Provention Bio has secured FDA approval for teplizumab, as a treatment to delay late-stage type 1 diabetes (T1D) in at-risk individuals – becoming the first disease ...

Teplizumab is thought to work by binding to CD3, preventing the activation of T cells that attack and kill insulin-producing pancreatic beta cells in the autoimmune disease.

A record entirely from the South, in a sector that has always been a thorn in the side. At the University Hospital of Palermo ...

Danat Al Emarat Hospital for Women & Children demonstrates success in using Teplizumab for Type 1 diabetes treatment in the UAE and wider region ...